Prostate Specific Antigen (PSA) Test Market Opportunities And Strategies 2024-2033 – Size, Growth Analysis, Outlook, Overview

The Prostate Specific Antigen (PSA) Test Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Prostate Specific Antigen (PSA) Test Market:
https://www.thebusinessresearchcompany.com/report/prostate-specific-antigen-psa-test-global-market-report

According to The Business Research Company’s Prostate Specific Antigen (PSA) Test Global Market Report 2024, The prostate specific antigen (psa) test market size has grown rapidly in recent years. It will grow from $3.66 billion in 2023 to $4.13 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%.  The  growth in the historic period can be attributed to increased awareness, aging population, medical advancements, clinical recommendations, pharmaceutical advancements.

The prostate specific antigen (psa) test market size is expected to see rapid growth in the next few years. It will grow to $6.4 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%.  The growth in the forecast period can be attributed to advancements in test accuracy, personalized medicine approach, personalized medicine approach, global aging population. Major trends in the forecast period include shift towards biomarker combinations, technological innovations, point-of-care testing, digital health integration, focus on early detection and prevention.

The increasing prevalence of prostate cancer is expected to propel the growth of the prostate-specific antigen (PSA) test market going forward. Prostate cancer is a condition in which cancer arises in the prostate gland, a component of the male and female reproductive systems. The prostate-specific antigen (PSA) test is commonly used as a screening tool for prostate cancer in men. It measures the level of PSA in the bloodstream, which will help with early detection and risk assessment. For instance, in March 2023, according to the reports shared by the American Society of Clinical Oncology (ASCO), a US-based professional oncology organization, in the US, an estimated 288,300 men were diagnosed with prostate cancer, and approximately 34,700 people died in 2023. Further, in 2020, globally, an estimated 1,414,259 people will be diagnosed with prostate cancer. Therefore, the rise in the prevalence of prostate cancer is driving the growth of the prostate-specific antigen (PSA) test market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12576&type=smp

The prostate specific antigen (psa) test market covered in this report is segmented –

1) By Type: Clinical Laboratory Improvement Amendments (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescence Immunoassay (FIA), Other Types

2) By Application: Screening, Post-Treatment Monitoring, Other Applications

3) By End User: Hospitals, Diagnostic Centers, Research Institutes, Other End Users

Top Major Players:
Hoffmann-La Roche AG
Bayer AG
Abbott Laboratories
Becton Dickinson and Company
PerkinElmer Inc

North America was the largest region in the prostate specific antigen (PSA) test market in 2023.

Technological advancements are the key trend gaining popularity in the prostate-specific antigen (PSA) test market. Major companies operating in the prostate-specific antigen (PSA) test market are developing advanced screening test tools to sustain their position in the market. For instance, in February 2023, LynxDx Inc., a US-based diagnostic company, launched MyProstateScore 2.0, a non-invasive urine prostate cancer screening test. This innovative test uses a combination of 18 biomarkers, including the novel gene fusion T2:ERG, to provide a personalized risk assessment for each patient. Additionally, this screening test offers highly accurate, stratified risk assessment insights to guide clinical decisions for patients with elevated prostate-specific antigen (PSA) or abnormal digital rectal exam (DRE) findings. Moreover, it has the potential to improve prostate cancer screening and treatment.

 The prostate specific antigen (psa) test market report table of contents includes:

1. Executive Summary
2. Prostate Specific Antigen (PSA) Test Market Characteristics
3. Prostate Specific Antigen (PSA) Test Market Trends And Strategies
4. Prostate Specific Antigen (PSA) Test Market – Macro Economic Scenario
5. Global Prostate Specific Antigen (PSA) Test Market Size and Growth
…
32. Global Prostate Specific Antigen (PSA) Test Market Competitive Benchmarking
33. Global Prostate Specific Antigen (PSA) Test Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Prostate Specific Antigen (PSA) Test Market
35.Prostate Specific Antigen (PSA) Test Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model